PMOS: New Name for Condition Affecting 1 in 8 Women

Imagine spending 25 years being told your debilitating symptoms are just "bad periods" when something far more complex is happening throughout your entire body. That's exactly what happened to Kate Chenoweth and millions of women with a condition doctors finally renamed in May.

The disorder once called polycystic ovarian syndrome (PCOS) is now polyendocrine metabolic ovarian syndrome, or PMOS. The shift might seem small, but for women like Chenoweth, who started seeing doctors at age 12 for periods lasting nine days and coming twice monthly, it's validation after years of being gaslit.

The old name created massive problems. Women were told they didn't have the condition because they didn't have cysts, when those "cysts" were never actually cysts at all. They were follicles holding immature eggs that couldn't be released, just one small piece of a body-wide hormone disorder.

PMOS affects up to 1 in 8 women globally and ranks among the leading causes of infertility. But fertility is only part of the story. Women with PMOS face irregular periods, insulin resistance, increased diabetes and heart disease risk, sleep apnea, fatty liver disease, and mental health challenges including depression and anxiety.

The new diagnostic guidelines drop the requirement for "cysts" on ovaries. Instead, doctors look for two out of three criteria: irregular menstrual cycles, elevated male hormones, and certain ultrasound findings. This simpler approach should catch cases that slipped through the cracks for decades.

Dr. Sun Kim, a Stanford endocrinologist, notes the condition isn't black and white. Some women primarily struggle with insulin resistance and metabolic issues. Others mainly experience irregular periods or conception challenges. Many face a combination of everything.

The Ripple Effect

The name change does more than clear up confusion. It repositions PMOS from a "women's health corner" issue to a metabolic syndrome worthy of serious research funding and clinical trials. Dr. Mibhali Bhalala at Kaiser Permanente Redwood City points out that medications developed for diabetes or weight loss might now be tested for PMOS treatment.

With 170 million people affected worldwide, this condition has been shockingly understudied. Moving away from the ovarian-centric name could finally attract the research dollars and attention that other metabolic conditions receive. That means better treatments, more clinical trials, and potentially life-changing therapies beyond the current standard of lifestyle changes, hormone replacement, and insulin medication.

The shift also reduces stigma. Some women felt embarrassed about having "cysts" on their ovaries or being labeled with a fertility condition. The new name acknowledges the full complexity without reducing women to their reproductive organs.

For Chenoweth, now 37 and finally diagnosed correctly, the validation changes everything: "That all these things are very much explainable, and also to a certain extent treatable, is really empowering and honestly life-changing in terms of just mindset and not feeling like it's just this endless abyss of no answers."